SEVERE CHOLESTATIC SYNDROME SECONDARY TO GRAVES’ DISEASE

Rodrigo Piltcher da Silva¹, Sabino Junior¹, Matheus Bernardon Morillos¹, Isabella Roque Miclos²,³, Letícia Schwerz Weinert⁴,⁵, Rogério Torres Marques⁶

Abstract

This paper reports a case of severe cholestasis as an atypical manifestation of Graves’ disease. It discusses the pathophysiology, the diagnosis and the investigation of this complication of hyperthyroidism as well as the impact of this finding on the therapeutic options for managing the disease.

Keywords: Graves’ disease; hyperthyroidism; cholestasis

Thyrotoxicosis is the clinical manifestation of an excessive release of thyroid hormones, associated or not with glandular hyperfunction. The main etiologies are Graves’ disease (GD), toxic adenoma, toxic multinodular goiter, subacute thyroiditis, and thyrotoxicosis factitia. GD is the most common form of hyperthyroidism, accounting for 60% to 80% of cases, with a women-to-men ratio of 5 to 10 and a higher incidence among those aged 40 to 60 years.

Initially described by Robert Graves in 1835, GD is an autoimmune disease which presents with some typical symptoms, such as weight loss, anxiety, tremors, ophthalmopathy and diffuse goiter. However, in the past few decades, several atypical clinical manifestations have been reported, such as anemia, thrombocytopenia, acute myocardial infarction, and jaundice. This report discusses the case of a patient with GD manifested as severe jaundice.

CASE REPORT

A 46-year-old male patient sought emergency care complaining of inappetence, dyspepsia, and weight loss of 16 kilograms over the course of 4 months, followed by abdominal discomfort and sudden onset of jaundice. He reportedly did not smoke, drink alcohol or use illicit drugs. He also reported having experienced symptoms of proptosis, fatigue and eventual palpitation during the previous year, which compromised his daily activities. Thus, he was referred for hospital admission because of suspected periampullary tumor.

In medical history-taking, the patient reported an admission due to abdominal discomfort, jaundice and palpitation two years earlier. The patient was diagnosed with atrial fibrillation, for which amiodarone was prescribed. He then experienced a spontaneous resolution of his abdominal discomfort and jaundice, with no etiological definition at that time.

In the current admission, the patient presented with a cholestatic syndrome, and physical examination revealed tachycardia, fibroelastic diffuse goiter (approximately 50 g), no palpable nodules, a fine tremor of hands, palpebral retraction, bilateral ocular proptosis, periorbital edema, conjunctival hyperemia and chemosis. An investigation revealed the following laboratory test results: thyroid-stimulating hormone (TSH): 0.01 mIU/L (reference range: 0.35-4.94 mIU/L), free T4: 4.53 ng/dL (reference range: 0.7-1.8 ng/dL), TSH receptor antibodies (TRAb): 17.99 U/L (reference range: <1.5 U/L), and anti–thyroid peroxidase antibodies (anti-TPO): 155.10 U/mL (reference range: <15 U/ml). A thyroid ultrasonography revealed a diffuse gland enlargement with homogeneous echotexture as well as reactive cervical lymph nodes. Therefore, the patient was
diagnosed with hyperthyroidism due to GD. Cardiac evaluation was performed with an electrocardiogram (ECG), and a transthoracic echocardiogram confirmed high-response atrial fibrillation and mild left atrial dilation.

Amiodarone was suspended due to a possible hepatotoxicity and interference on thyroid function, and beta-blockers were administered. Concomitantly, an extensive investigation was performed in order to rule out primary liver diseases. Abdominal ultrasonography, abdominal computed tomography (CT), magnetic resonance cholangiography (MRC), and duodenoscopy did not reveal any hepatobiliary alterations. The laboratory evaluation showed negative serology for HIV, hepatitis A, B, and C viruses, anti-mitochondrial and anti-smooth muscle antibodies; ceruloplasmin level of 38.7 mg/dL (reference range: 21-53 mg/dL); non-reactive anti-nuclear antibodies (ANA); ferritin level of 340 mg/dL (reference range: 20-330 mg/dL); transferrin saturation index of 40% (reference range: 20-45%); alpha-1-antitrypsin level of 158 mg/dL (reference range: 90-200 mg/dL); immunoglobulin G (IgG) level of 1,645 mg/dL (reference range: 700-1,600 mg/dL); negative direct Coombs test.

Since severe cholestatic syndrome is a rare event in hyperthyroidism, as described by Wang et al., a percutaneous hepatic biopsy was performed to exclude other etiologies. The biopsy showed congestion of sinusoids, moderate inflammatory infiltrates, steatosis, and fibroblast foci, which constitute a set of nonspecific findings.

During hospitalization, the patient had variable liver test results (Table). At first, there was a reduction in the values after suspension of amiodarone, which suggested its involvement in the etiology of the case. However, that was followed by a new elevation in the results, thus refuting the hypothesis.

Because of the severe evolution of liver disease, the hypothesis that cholesis was secondary to hyperthyroidism, the impossibility of treatment with tapazole and the presence of ophthalmopathy, the chosen approach was total thyroidectomy. Control of liver function and cholestasis was recovered after the procedure on April 12, 2018, and laboratory results were normal after 30 days, as shown in the Table.

### DISCUSSION

The present study reports the case of a patient who presented with severe cholestatic syndrome secondary to GD. Although a study conducted by Gürlek et al. has demonstrated that the presence of hepatic impairment is found in 60% of patients with hyperthyroidism, cases of severe cholestasis are rare (around 6.6%) in the literature. Thus, in order to be sure that GD was the etiology of hepatic dysfunction in the current patient, other conditions had to be excluded through complementary laboratory tests, imaging tests and liver biopsy. Moreover, observing whether cholestasis would improve after appropriate treatment of thyrotoxicosis was necessary.

Among the differential diagnoses for jaundice in patients with GD are the thyrotoxic crisis itself, the use of antithyroid drugs (thionamides), autoimmune hepatitis, primary biliary cholangitis (PBC), Gilbert’s syndrome, hepatic congestion secondary to heart failure, or thrombosis of the hepatic artery due to atrial fibrillation. In addition, other common causes of hyperbilirubinemia unrelated to this thyroid disorder should be excluded, such as viral hepatitis, alcohol abuse, cholangitis, and other medications.

There is no consensus regarding the mechanism of liver injury due to hyperthyroidism. The most accepted theory is that hypoxia occurs in centrilobular regions due to an increase in oxygen demand without adequate growth of hepatic blood flow. Liver biopsy findings are nonspecific, consisting of mild lobular inflammatory infiltrate with neutrophils, eosinophils, and lymphocytes associated with Kupffer cell hyperplasia, as well as intrahepatic cytoplasmic cholestasis.

Regarding treatment, total thyroidectomy was the best option for this patient instead of thionamides and radioactive iodine because of the liver dysfunction and ophthalmopathy. In Brazil, tapazole is the first therapeutic choice for GD. However, in the present case, hepatotoxicity inherent to thionamides limited their use.

In conclusion, this case report draws attention to an unusual presentation of GD with hepatic dysfunction. Abnormal liver function test results are

### Table: Liver function test results during hospitalization.

<table>
<thead>
<tr>
<th></th>
<th>TB/DB (mg/dL)</th>
<th>AST/ALT (U/L)</th>
<th>GGT (U/L)</th>
<th>ALP (U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/07</td>
<td>24.6/20</td>
<td>92/93</td>
<td>215</td>
<td>225</td>
</tr>
<tr>
<td>02/11</td>
<td>13.9/11.4</td>
<td>74/99</td>
<td>195</td>
<td>198</td>
</tr>
<tr>
<td>02/26</td>
<td>3.5/3.4</td>
<td>25/31</td>
<td>223</td>
<td>167</td>
</tr>
<tr>
<td>03/29</td>
<td>11.4/10.6</td>
<td>28/21</td>
<td>216</td>
<td>243</td>
</tr>
<tr>
<td>04/12</td>
<td>24/22.2</td>
<td>32/23</td>
<td>216</td>
<td>274</td>
</tr>
<tr>
<td>04/18</td>
<td>12.1/11.3</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>05/02</td>
<td>3.8/3.7</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>07/16</td>
<td>0.83/0.57</td>
<td>22/10</td>
<td>92</td>
<td>191</td>
</tr>
<tr>
<td>RR</td>
<td>&lt;1.2/+0.3</td>
<td>&lt;37/+41</td>
<td>&lt;73</td>
<td>&lt;110</td>
</tr>
</tbody>
</table>

Total bilirubin (TB), direct bilirubin (DB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), reference range (RR).
Cholestasis due to Graves’ disease

often observed in patients with hyperthyroidism, and clinicians should be aware of this situation. However, this patient presented with severe cholestasis, a rare condition that requires prompt diagnosis, etiological investigation and management. Appropriate diagnosis and treatment of hyperthyroidism was essential for improving the patient’s symptoms and liver dysfunction.

Conflicts of Interest
The authors declare no conflicts of interest.

REFERENCES


Received: Oct 16, 2018
Accepted: Apr 12, 2019